ReviewRecent advances in drug delivery and formulation2025
Pharmaceutical Manufacturing with Additive Technology: A Key Driver of Industry 4.0 Integration.
Review in Recent advances in drug delivery and formulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Additive Manufacturing (AM) has emerged as a transformative force in the pharmaceutical industry, establishing itself as a cornerstone of Industry 4.0. This review explores the capability of 3D printing (3DP) technologies that facilitate the creation of individualized dosage forms, precise drug release control, and customized drug delivery systems. These innovations have significantly improved treatment outcomes and efficiency. The study identifies key challenges hindering the widespread adoption of AM in pharmaceuticals, including issues related to material selection, regulatory compliance, and process efficiency. By analyzing the interrelationship between AM and the fundamental pillars of Industry 4.0, we demonstrate how AM can optimize manufacturing costs, reduce production time, and minimize waste. The review also presents a strategic roadmap for future research, emphasizing the need for interdisciplinary collaboration to overcome regulatory barriers, develop medical-grade materials, and optimize manufacturing processes through advanced computational models and machine learning. This approach aims to accelerate the integration of AM into pharmaceutical manufacturing, ultimately enhancing personalized patient care and therapeutic effectiveness.
Indexed as
Identifiers
40045864What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.